Study of GO-203-2C Given Intravenously in Patients With Advanced Solid Tumors Including Lymphomas

Summary

This clinical trial is about testing GO-203-2c, which is a newly discovered compound that binds to an oncoprotein (a cancer causing protein) called MUC1 (which is over-expressed in many cancers). By binding to MUC1, GO-203-2c eventually causes tumor cell death in laboratory studies. This study is being done to: * Test the safety of GO-203-2c and see what effects (good and bad) it has on you and your cancer * Find the highest dose of GO-203-2c that can be given without causing bad side effects * Examine how much GO-203-2c is in the blood at certain times after it is given and how quickly the body gets rid of it * Observe whether there is any effect of GO-203-2c on the size and activity of cancer in your body

Timeline

Start

2011-01

Primary completion

2013-05

Completion

2013-05

Publications

• Gorodetska I, Samusieva A, Lahuta T, Ponomarova O, Socha O, Kozeretska I. Exploring New Frontiers: Alternative Breast Cancer Treatments Through Glycocalyx Research. Breast J. 2025 May 22;2025:9952727. doi: 10.1155/tbj/9952727. eCollection 2025.

Drugs

Indications